Daisuke Watanabe

Dr. Daisuke Watanabe


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2017 in Gut
Verified
Journal Article
Open access
PDF file
TKTakuji Kawamura
Takuji Kawamura
YTYoji Takeuchi
Yoji Takeuchi
SASatoshi Asai
Satoshi Asai
IYIsao Yokota
Isao Yokota
EAEisuke Akamine
Eisuke Akamine
KTKiyohito Tanaka
Kiyohito Tanaka
Objective To investigate the success rate of cold snare polypectomy (CSP) for complete resection of 4–9 mm colorectal adenomatous polyps compared with that of hot snare polypectomy (HSP). Design A prospective, multicentre, randomised controlled, parallel, non-inferiority trial conducted in 12 Japanese endoscopy units. Endoscopically diagnosed sessile adenomatous polyps, 4–9 mm in size, were randomly assigned to the CSP or HSP group. After complete removal of the polyp using the allocated technique, biopsy specimens from the resection margin after polypectomy were obtained. The primary endpoint was the complete resection rate, defined as no evidence of adenomatous tissue in the biopsied specimens, among all pathologically confirmed adenomatous polyps. Results A total of 796 eligible polyps were detected in 538 of 912 patients screened for eligibility between September 2015 and August 2016. The complete resection rate for CSP was 98.2% compared with 97.4% for HSP. The non-inferiority of CSP for complete resection compared with HSP was confirmed by the +0.8% (90% CI −1.0 to 2.7) complete resection rate (non-inferiority p<0.0001). Postoperative bleeding requiring endoscopic haemostasis occurred only in the HSP group (0.5%, 2 of 402 polyps). Conclusions The complete resection rate for CSP is not inferior to that for HSP. CSP can be one of the standard techniques for 4–9 mm colorectal polyps. (Study registration: UMIN000018328)

1 August 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
STShinwa Tanaka
Shinwa Tanaka
TTTakashi Toyonaga
Takashi Toyonaga
FKFumiaki Kawara
Fumiaki Kawara
DWDaisuke Watanabe
Daisuke Watanabe
NHNamiko Hoshi
Namiko Hoshi
YKYuzo Kodama
Yuzo Kodama

2 November 2017 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
DWDaisuke Watanabe
Daisuke Watanabe
TTTakashi Toyonaga
Takashi Toyonaga
MOMakoto Ooi
Makoto Ooi
TYTetsuya Yoshizaki
Tetsuya Yoshizaki
YOYoshiko Ohara
Yoshiko Ohara
TATakeshi Azuma
Takeshi Azuma

27 October 2021 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
DWDaisuke Watanabe
Daisuke Watanabe
YGYijie Guo
Yijie Guo
NKNobuhiko Kamada
Nobuhiko Kamada
The inflammasome is a cytosolic multiprotein complex that plays a crucial role in inflammation and cell death. The sensor proteins in the inflammasome complex detect various microbial and endogenous stimuli, leading to subsequent caspase activation. The activation of caspases results in the maturation of pro‐inflammatory cytokines IL‐1β and IL‐18 or pyroptosis. Inflammasome dysfunction is associated with the pathogenesis of various diseases, including autoimmune disease and cancer. It appears that the interactions between the gut microbiota and the inflammasome play crucial roles in the gastrointestinal tract. The gut microbiota induces the expression and activation of inflammasome proteins, which contribute to both homeostasis and disease in the gut. Likewise, although controversial, mounting evidence suggests that inflammasome activation can modulate the composition of the gut microbiota, which, in turn, affects disease progression. In this review, we summarize the current concepts and recent insights linking the inflammasome and gut commensal microorganisms. We describe how the reciprocal interaction between the inflammasome and the commensal microbiota relates to physiological and pathophysiological consequences in the host.

18 March 2016 in Endoscopy
Verified
Journal Article
Closed access
PDF file
TYTetsuya Yoshizaki
Tetsuya Yoshizaki
TTTakashi Toyonaga
Takashi Toyonaga
STShinwa Tanaka
Shinwa Tanaka
YOYoshiko Ohara
Yoshiko Ohara
FKFumiaki Kawara
Fumiaki Kawara
TATakeshi Azuma
Takeshi Azuma
Background and study aim: Endoscopic submucosal dissection (ESD) has been applied to treat early colorectal cancers. The aim of this study was to clarify the clinical course of ESD for lesions involving the ileocecal valve (ICV) by evaluating the successful resection rates, and the risk and frequency of adverse events. Patients and methods: The outcome of ESD on 38 ICV lesions was compared with the outcome of 132 cecal lesions that did not involve the ICV or appendiceal orifice during the same study period. The factors related to longer procedure time, postoperative stricture development, and tumor recurrence were investigated for ESD of ICV lesions. Results: There was no significant difference between the ICV and non-ICV groups in the en block resection rates. The median procedure time was significantly longer in the ICV group than in the non-ICV group, with a point estimate of the difference of 37 minutes (95 % confidence interval [CI] 20.00 to 56.00; P < 0.01). None of the patients developed symptomatic post-ESD stricture or tumor recurrence. ESD procedure duration was ≥ 120 minutes in 16 lesions and < 120 minutes in 22 lesions of the ICV group. A specimen diameter of ≥ 40 mm and tumor extension into terminal ileum were factors related to a longer procedure time (odds ratio [OR] 8.40, 95 %CI 1.53 to 46.10, P = 0.01; OR 10.60, 95 %CI 2.17 to 51.40, P < 0.01, respectively). Conclusions: ICV lesions can be resected by ESD without major adverse events or causing symptomatic stricture development. However, ESD for ICV lesions should be performed only by expert endoscopists, as the procedure requires accomplished endoscopic skill and experience.

21 November 2017 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
DWDaisuke Watanabe
Daisuke Watanabe
MKMichiyo Koyanagi-Aoi
Michiyo Koyanagi-Aoi
MTMariko Taniguchi-Ikeda
Mariko Taniguchi-Ikeda
YYYukiko Yoshida
Yukiko Yoshida
TATakeshi Azuma
Takeshi Azuma
TATakashi Aoi
Takashi Aoi
γδT cells constitute a small proportion of lymphocytes in peripheral blood. Unlike αβT cells, the anti-tumor activities are exerted through several different pathways in a MHC-unrestricted manner. Thus, immunotherapy using γδT cells is considered to be effective for various types of cancer. Occasionally, however, ex vivo expanded cells are not as effective as expected due to cell exhaustion. To overcome the issue of T-cell exhaustion, researchers have generated induced pluripotent stem cells (iPSCs) that harbor the same T-cell receptor (TCR) genes as their original T-cells, which provide nearly limitless sources for antigen-specific cytotoxic T lymphocytes (CTLs). However, these technologies have focused on αβT cells and require a population of antigen-specific CTLs, which are purified by cell sorting with HLA-peptide multimer, as the origin of iPS cells. In the present study, we aimed to develop an efficient and convenient system for generating iPSCs that harbor rearrangements of the TCRG and TCRD gene regions (γδT-iPSCs) without cell-sorting. We stimulated human whole peripheral blood mononuclear cell (PBMC) culture using Interleukin-2 and Zoledronate to activate γδT cells. Gene transfer into those cells with the Sendai virus vector resulted in γδT cell-dominant expression of exogenous genes. The introduction of reprogramming factors into the stimulated PBMC culture allowed us to establish iPSC lines. Around 70% of the established lines carried rearrangements at the TCRG and TCRD gene locus. The γδT-iPSCs could differentiate into hematopoietic progenitors. Our technology will pave the way for new avenues toward novel immunotherapy that can be applied for various types of cancer. Stem Cells Translational Medicine 2017